首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5108篇
  免费   305篇
  国内免费   43篇
耳鼻咽喉   45篇
儿科学   252篇
妇产科学   62篇
基础医学   683篇
口腔科学   218篇
临床医学   437篇
内科学   1280篇
皮肤病学   139篇
神经病学   269篇
特种医学   342篇
外科学   586篇
综合类   52篇
一般理论   1篇
预防医学   246篇
眼科学   79篇
药学   336篇
中国医学   13篇
肿瘤学   416篇
  2021年   90篇
  2019年   81篇
  2018年   116篇
  2017年   66篇
  2016年   88篇
  2015年   118篇
  2014年   116篇
  2013年   210篇
  2012年   202篇
  2011年   211篇
  2010年   162篇
  2009年   117篇
  2008年   162篇
  2007年   181篇
  2006年   192篇
  2005年   190篇
  2004年   135篇
  2003年   158篇
  2002年   175篇
  2001年   126篇
  2000年   166篇
  1999年   125篇
  1998年   114篇
  1997年   111篇
  1996年   126篇
  1995年   88篇
  1994年   99篇
  1993年   88篇
  1992年   92篇
  1991年   82篇
  1990年   94篇
  1989年   101篇
  1988年   88篇
  1987年   71篇
  1986年   69篇
  1985年   57篇
  1984年   68篇
  1983年   40篇
  1982年   34篇
  1981年   43篇
  1980年   51篇
  1977年   41篇
  1976年   42篇
  1975年   41篇
  1965年   51篇
  1964年   50篇
  1963年   47篇
  1962年   41篇
  1961年   41篇
  1960年   65篇
排序方式: 共有5456条查询结果,搜索用时 15 毫秒
991.
BackgroundTreatment options remain limited for patients with castration-resistant prostate cancer (CRPC). We evaluated eribulin mesylate (E7389), a nontaxane halichondrin B analog microtubule inhibitor, in patients with metastatic CRPC with or without previous taxane exposure.Patients and methodsMen with histologically proven CRPC, with or without prior taxane exposure, were enrolled in an open-label, single-arm phase II trial. Patients received eribulin mesylate 1.4 mg/m2 as a 2- to 5-min i.v. bolus infusion on days 1 and 8 of a 21-day cycle. The primary efficacy end point was prostate-specific antigen (PSA) response rate.ResultsIn total, 108 patients were assessable for safety (50 were taxane-pretreated) and 105 for efficacy in the per-protocol population. The median age of patients was 71 years and median number of cycles was 4. PSA decreases of ≥50% were achieved in 22.4% and 8.5% of taxane-naive and taxane-pretreated patients, respectively. The most common grade 3/4 adverse event was neutropenia, seen in 22.4% of chemo-naive and 40% of taxane-pretreated men. Grade 3 peripheral neuropathy occurred in none of the taxane-naive patients and 6.0% of taxane-pretreated patients.ConclusionEribulin mesylate demonstrated activity and a relatively favorable toxicity profile in metastatic CRPC.  相似文献   
992.
BackgroundIn 25 % to 50 % of patients with port wine stains treated with pulsed dye laser (even in multiple sessions), only a partial improvement is obtained that is often unsatisfactory for the patient. Various factors have been proposed to explain the resistance to treatment, such as the presence of deep, small-caliber, or very thick vessels that cannot be coagulated with a single laser pulse. Certain mathematical models suggest that multiple pulses would be effective in coagulating those vessels without losing the selectivity of photothermolysis, since more energy could be delivered to the target structures without damaging the surrounding tissue. The aim of this study was to assess the efficacy and selectivity of photothermolysis with multiple laser pulses.MethodsTwelve patients with port wine stains were included in the study. Various areas of each lesion were treated with pulsed dye laser (Candela V-beam, 595 nm) using different parameters. Immediately afterwards, the treated areas were biopsied.ResultsThe risk of exceeding an appropriate dose was greater with small spot size, long pulse duration, short intervals between pulses, and high fluences. Heat damage was less with spots of 10 mm, short pulses, intervals of 1 minute between pulses, and low fluences. In selected cases, multiple pulses were effective and selective where single pulses did not successfully coagulate the vessels.ConclusionsOur results indicate the enormous possibilities of multiple laser pulses for the treatment of refractory vascular lesions. In addition, we have addressed the variables defining the complex thermodynamic interaction between the laser and the cutaneous tissue and indicated the safest parameters. We discuss the possible usefulness of this approach with other lasers and skin diseases.  相似文献   
993.
994.
995.
996.
This study evaluated the productive efficiency of 112 hospitals under the Unified National Health System (SUS) in the State of Santa Catarina, Brazil. The objective was to verify which hospitals apply the available resources efficiently. The research was based on data from 2003 collected from the SUS Hospital Data System (SIH-SUS). Data Envelopment Analysis (DEA) was applied under the assumption of variable returns to scale. The study focused exclusively on general hospitals with similar characteristics in terms of size and specialization. The results identified 23 efficient hospitals and efficiency targets for each hospital. According to the empirical model, the number of hospitalizations with discharges could be increased by 15%. Application of an input reduction model would result in savings of 25% on human resources (physicians and nurse technicians), 17% on hospital beds, and 13% on admissions costs for the overall hospital system.  相似文献   
997.

Purpose

To compare clinical and computed tomography (CT) measures in extension, 20° and 30° of flexion of symptomatic knees of patient with idiopathic patellofemoral pain syndrome with the contra lateral asymptomatic knee.

Materials and methods

Knees of 52 consecutive patients with idiopathic patellofemoral pain were studied with CT. In 28 patients this condition was unilateral and asymptomatic knee was used as control; 76 knees were symptomatic.

Results

In patients with idiopathic patellofemoral pain we found a greater Q angle and internal condylar facet width in symptomatic knees with regard to asymptomatic knees.

Conclusion

Greater Q angle and medial condylar facet can lead to overpressure on the medial knee compartment during maneuvers that increase contact between patella and medial condylar facet, such as knee flexion and squatting, contributing to development of idiopathic patellofemoral pain.  相似文献   
998.
999.
1000.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号